Hematólogica

24/04/2026

Asiste al XI Congreso SOMETH 2026 en Guadalajara. Evento académico de referencia en trombosis y hemostasia con expertos nacionales e internacionales.

24/04/2026

Nature Reviews Clinical Oncology: Platelets can promote cancer progression through either direct and indirect mechanisms, and they can also suppress tumour progression in certain contexts. The authors of this Review discuss how insights on these properties have been leveraged to develop cancer therapies in which platelets are engineered to act as targeted delivery vehicles or as active effector cells, outlining opportunities and challenges for clinical translation.

Link to the Review in the comments.

24/04/2026

How should we manage primary mediastinal B-cell lymphoma patients with relapsed/refractory disease after frontline DA-EPOCH-R? A retrospective review of 107 patients helps to find answers.
https://haematologica.org/article/view/12964

22/04/2026

👉🏻Save the date‼️
📅8 de mayo
Highlights of the EBMT 2026 Meeting.

+INFO: [email protected]

The EBM

22/04/2026

🚨Ateneo de la SAH: "Crónica de una neoplasia mieloproliferativa"
Modalidad virtual, el 24 de abril a las 17hs.
Comenta el caso el Dr. Mrinal Patnaik. No te lo pierdas!
Ingresa a través del link👇
https://us02web.zoom.us/webinar/register/WN_e9gHFRuGTCC4ewQV91VzEw #/registration

22/04/2026

Para recordar 👇

22/04/2026

Neutrophils, the most abundant immune cells in human blood, play a pivotal role in host defense against invading pathogens, but are also capable of inflicting tissue damage, a common feature of diverse inflammatory pathologies. Therefore, blocking neutrophil influx has been considered an interesting therapeutic concept in diseases with overwhelming neutrophil responses. Using several in vivo and in vitro approaches a new study investigates the mode of action of ladarixin, a dual non-competitive inhibitor of chemokine receptors CXCR1 and CXCR2, in blocking neutrophil recruitment during inflammation.
https://haematologica.org/article/view/12235

22/04/2026

07/02/2026

La Sociedad Argentina de Hematología acompaña esta iniciativa para que usted reciba las actualizaciones más recientes del ASH Annual Meeting, adaptadas para América Latina.

Temas incluyen:
🧬 Leucemias (LLA, LMA, LMC)
🩸 Linfomas (agresivos, indolentes, de células del manto, T)
⚠️ Mieloma, hemoglobinopatías, trastornos hemorrágicos, insuficiencia medular, SMD, TMA, HPN
💊 CAR-T, trasplante, inmunoterapias, terapias dirigidas
🌍 NMP, tromboembolismo venoso, hemólisis y complemento

👉 Regístrese ahora: hematology.org/Highlights-LA

07/02/2026